开云app官网登录入口网页版-官方正版

#非鳞状NSCLC#

7篇内容 | 1007人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2177968, encodeId=56e821e7968f0, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=e944823960d' target=_blank style='color:#2F92EE;'>#肺鳞癌#</a> <a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a> <a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=肺鳞癌vs非鳞癌，哪些PD-L1表达的患者用免疫治疗效果更好?, objectType=article, longId=807269, objectId=52e980e269fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=52e980e269fc, replyNumber=0, likeNumber=114, createdTime=2023-12-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=52e980e269fc, moduleTitle=肺鳞癌vs非鳞癌，哪些PD-L1表达的患者用免疫治疗效果更好?, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=52e980e269fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2076172, encodeId=f3af20e6172a2, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！, objectType=article, longId=215518, objectId=62cd2155186f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cd2155186f, replyNumber=0, likeNumber=89, createdTime=2021-11-21, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cd2155186f, moduleTitle=J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=62cd2155186f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2076171, encodeId=165f20e6171ec, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), objectType=article, longId=199903, objectId=f051199903bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f051199903bb, replyNumber=0, likeNumber=83, createdTime=2020-11-24, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f051199903bb, moduleTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f051199903bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2076170, encodeId=8be820e6170d8, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC, objectType=article, longId=163233, objectId=c8c0163233da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8c0163233da, replyNumber=0, likeNumber=103, createdTime=2019-08-18, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8c0163233da, moduleTitle=刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c8c0163233da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2076168, encodeId=6d9e20e616810, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=NEJM：Pembro联合化疗：非鳞状NSCLC一线治疗方案, objectType=article, longId=135819, objectId=070e135819cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=070e135819cd, replyNumber=0, likeNumber=64, createdTime=2019-01-28, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=070e135819cd, moduleTitle=NEJM：Pembro联合化疗：非鳞状NSCLC一线治疗方案, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=070e135819cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2076169, encodeId=87e120e616936, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=欧盟监管机构批准默克的Keytruda联合化疗药物一线治疗非鳞状NSCLC, objectType=article, longId=148603, objectId=a63d14860340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a63d14860340, replyNumber=0, likeNumber=105, createdTime=2019-06-27, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a63d14860340, moduleTitle=欧盟监管机构批准默克的Keytruda联合化疗药物一线治疗非鳞状NSCLC, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a63d14860340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2076167, encodeId=46ec20e61676a, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=Lancet：ALK重排的非鳞状NSCLC患者ceritinib和铂类为基础的化疗哪个更好？, objectType=article, longId=88050, objectId=e01e880500f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01e880500f, replyNumber=0, likeNumber=114, createdTime=2017-12-24, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01e880500f, moduleTitle=Lancet：ALK重排的非鳞状NSCLC患者ceritinib和铂类为基础的化疗哪个更好？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e01e880500f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2076166, encodeId=e83820e6166ed, content=<a href='/topic/show?id=435599e72f3' target=_blank style='color:#2F92EE;'>#非鳞状NSCLC#</a>, objectTitle=EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存, objectType=article, longId=36798, objectId=18bc36e9818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18bc36e9818, replyNumber=0, likeNumber=115, createdTime=2014-07-01, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18bc36e9818, moduleTitle=EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=18bc36e9818)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

非鳞状NSCLC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #免疫治疗# #肺鳞癌# #PD-L1# #非鳞状NSCLC#

肺鳞癌vs非鳞癌，哪些PD-L1表达的患者用免疫治疗效果更好?

2023-12-29发表于上海

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！

2021-11-21

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11)

2020-11-24

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC

2019-08-18

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

NEJM：Pembro联合化疗：非鳞状NSCLC一线治疗方案

2019-01-28

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

欧盟监管机构批准默克的Keytruda联合化疗药物一线治疗非鳞状NSCLC

2019-06-27

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

Lancet：ALK重排的非鳞状NSCLC患者ceritinib和铂类为基础的化疗哪个更好？

2017-12-24

zhty5337 (审核中...)

前往app查看评论内容

#非鳞状NSCLC#

EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存

2014-07-01

科室
- - 订阅+
  - 更多科室
工具
服务